Prophylaxis and High-Risk Groups
On July 28, 2014, The American Academy of Pediatrics (AAP) released updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for RSV infection.
For specific and latest recommendations, please consult this AAP guidance.
- Page last reviewed: August 6, 2014
- Page last updated: August 6, 2014
- Content source: